# Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies

## TL;DR

This paper reviews the current understanding of oligometastatic bladder cancer, focusing on its definition, diagnosis, and treatment options, and highlights the need for better biomarker-driven clinical trials.

## Contribution

The paper emphasizes the importance of integrating tumor biology and molecular data into the definition and treatment of oligometastatic bladder cancer.

## Key findings

- Current definitions of OMBC rely on lesion count and distribution but miss molecular heterogeneity.
- Advances in PET/CT and MRI improve detection of small-volume disease.
- Circulating tumor DNA and liquid biopsy show promise for detecting micrometastases.

## Abstract

Oligometastatic bladder cancer (OMBC) is increasingly described as an intermediate state between localised and widespread metastatic disease, although its definition and optimal management remains uncertain. This narrative review summarises current evidence relating to the definition, diagnosis, and treatment of OMBC, with an emphasis on recent advances that may refine patient selection and decision-making. We discuss existing anatomical definitions based on metastatic burden and distribution, alongside emerging data highlighting the importance of tumour biology, molecular alterations, and treatment responsiveness. Recent advances in imaging modalities, including PET/CT and MRI, are discussed, and we explore the role of circulating biomarkers such as tumour DNA for the detection of micrometastatic disease. Furthermore, we discuss therapeutic strategies including systemic therapy, metastasis-directed interventions, and consolidative approaches. Ultimately, future biomarker-driven prospective clinical trials are necessary to optimise treatment sequencing and clarify the role of precision-based multimodal therapy in OMBC.

Background: Oligometastatic bladder cancer (OMBC) is increasingly recognised as an intermediate state between localised and widespread metastatic disease, although its definition and optimal management remain uncertain. Patients with OMBC have a generally more favourable prognosis compared to patients with metastatic disease. However, its definition, diagnostic criteria, and optimal management remain poorly standardised. Methods: This narrative review summarises current evidence on the definitions, diagnostic approaches, and treatment strategies for OMBC, with an emphasis on emerging biological and molecular insights that may refine disease classification and guide therapy. Results: Existing definitions of OMBC rely on lesion count and anatomical distribution, overlooking molecular and clinicopathological heterogeneity that influences prognosis and treatment response. Advances in Positron Emission Tomography (PET)/Computed Tomography (CT) and magnetic resonance imaging (MRI) have improved detection of small-volume disease, while liquid biopsy and circulating tumour DNA show promise for assessing micrometastatic burden. Therapeutic approaches, including metastasis-directed and consolidative therapies, are under investigation. Nonetheless, most data are derived from small, retrospective series, and evidence from prospective studies remains limited. Conclusions: Prospective, biomarker-integrated, and randomised trials are essential to refine definitions, optimise patient selection for therapy, and define the role of precision-based multimodal therapy in OMBC management.